Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer

KRAS activating mutations, which are present in more than 90% of pancreatic cancers, drive tumor dependency on the RAS/mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT signaling pathways. Therefore, combined targeting of RAS/MAPK and PI3K/AKT signaling pathways may be...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ji Eun, Woo, Min Gyu, Jung, Kyung Hee, Kang, Yeo Wool, Shin, Seung-Min, Son, Mi Kwon, Fang, Zhenghuan, Yan, Hong Hua, Park, Jung Hee, Yoon, Young-Chan, Kim, Yong-Sung, Hong, Soon-Sun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Applied Pharmacology 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047487/
https://www.ncbi.nlm.nih.gov/pubmed/34663758
http://dx.doi.org/10.4062/biomolther.2021.145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047487/
https://www.ncbi.nlm.nih.gov/pubmed/34663758
http://dx.doi.org/10.4062/biomolther.2021.145

Ejemplares similares